Gastrointestinal Therapeutics Market By Drug Class (Biologics, Proton Pump Inhibitors, Aminosalicylates, Antacids, Laxatives, H2 Antagonists, Others), By Application (Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

Gastrointestinal Therapeutics Market

The Gastrointestinal Therapeutics Market is likely to experience a significant growth rate of 5.0% from 2023-2032 owing to increase in demand for gastrointestinal drugs from pharmaceutical sector – .  Gastrointestinal therapeutics refers to the branch of medicine and healthcare focused on the diagnosis, treatment, and management of disorders and conditions affecting the gastrointestinal (GI) tract. Gastrointestinal therapeutics involves a range of medical approaches, including medications, surgical interventions, lifestyle modifications, and dietary recommendations, aimed at addressing various GI disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), peptic ulcers, diarrhea, and more. The field aims to alleviate symptoms, promote healing, manage complications, and improve overall well-being for individuals experiencing gastrointestinal health issues. 

Key factors driving the growth of the gastrointestinal therapeutics market include the rise in prevalence of rise in prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and others. For instance, in 2022, the American Cancer Society estimates a total 106,180 new cases of colon cancer and 46,050 cases of rectal cancer in U.S. This growing incidence of gastrointestinal diseases is driving the demand for gastrointestinal therapeutics as a treatment option. In addition, the rise in awareness about gastrointestinal diseases, advancements in diagnostic techniques resulted in early detection and diagnosis of gastrointestinal diseases. This led to an increase in the demand for gastrointestinal therapeutics. 

In addition, growing awareness about early diagnosis of gastrointestinal diseases and their management in developing countries led to the increase in demand for the gastrointestinal therapeutics drugs that propels the market growth. Furthermore, ongoing research and development efforts aim to improve the efficacy, safety, and specificity of gastrointestinal therapeutics medications are anticipated to propel the market growth. 

Moreover, the rise in geriatric population suffering from gastrointestinal diseases have a significant impact on driving the growth of the gastrointestinal therapeutics market. The geriatric population is more susceptible to a variety of GI disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, constipation, diverticular disease, and colorectal cancer. The higher disease burden among older adults leads to an increased demand for effective treatment options, thereby driving market growth.

The market also offers growth opportunities to the key players in the market. The rise in R&D activities within the field of gastrointestinal therapeutics offers significant opportunities for market growth. As scientific understanding of gastrointestinal diseases deepens and innovative treatment approaches emerge, these R&D efforts pave the way for new therapeutic options, improved patient outcomes, and expanded market potential. For instance, in June 2023 Erasca, Inc. conducted a clinical trial to study ERAS-007 in patients with advanced gastrointestinal malignancies. In addition, the rise in funding activities, demand for better healthcare facilities and surge in need for gastrointestinal therapeutics thereby provide the lucrative opportunity to the market growth. 

The gastrointestinal therapeutics market is segmented into m drug class, application, distribution channel and region. On the basis of drug class, the market is categorized into biologics, proton pump inhibitors, aminosalicylates, antacids, laxatives, H2 antagonists, and others. By application, the market is classified into inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, and others. The inflammatory bowel disease segment is further categorized into Crohn’s disease and ulcerative colitis. The peptic ulcer disease segment further categorized into the gastric ulcer and duodenal ulcer. On the basis of distribution channel, it is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific ((Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key players profiled in the study include AstraZeneca plc, AbbVie Inc., Pfizer Inc., AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Organon Group of Companies, Bausch Health Companies Inc., Cosmo Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Bristol-Myers Squibb Company. The players in the market have been actively engaged in the adoption of various strategies such as product launch, product approval, and clinical trials to remain competitive and gain an advantage over the competitors in the market. For instance, in September 2021, Takeda Pharmaceutical Company Limited announced that it has received approval from the Japan Ministry of Health, Labour and Welfare to manufacture and market Alofisel (darvadstrocel) for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn's disease (CD).

Key Market Insights 

By drug class, the biologics segment was the largest revenue contributor to the market and is estimated to reach $25.52 billion by 2032, with a highest CAGR of 6.9%. 

By application, the inflammatory bowel disease segment dominated the global market with a highest CAGR of 5.5% during the forecast period. 

Based on distribution channel, the drug store and retail pharmacies segment was the largest revenue contributor to the market. However, the online providers segment is anticipated to grow at the highest CAGR of 5.6% during the forecast period. 

Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The gastrointestinal therapeutics market was valued at $39.5 billion in 2022 and is estimated to reach $64.5 billion by 2032, exhibiting a CAGR of 5.0% from 2023 to 2032. Gastrointestinal therapeutics refers to the branch of medical science and healthcare focused on the diagnosis, treatment, and management of disorders and diseases affecting the gastrointestinal (GI) tract. The GI tract is a complex system responsible for the digestion and absorption of food, as well as the elimination of waste. It includes organs such as the mouth, esophagus, stomach, small intestine, large intestine (colon), rectum, and anus. Medications used in GI therapeutics include antacids, proton pump inhibitors, antiemetics, laxatives, antispasmodics, anti-inflammatory drugs, immunosuppressants, and others.

Ongoing research in fields such as gastroenterology, immunology, and microbiology contribute to a deeper understanding of the underlying causes and mechanisms of gastrointestinal disorders. This knowledge leads to the development of targeted therapies and more personalized treatment approaches. The gastrointestinal therapeutics market has experienced significant growth owing to the rise in prevalence of gastrointestinal disorders, such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). For instance, according to the National Center for Biotechnology and Information (NCBI) in 2022, gastroesophageal reflux disease (GERD) is one of the most commonly diagnosed digestive disorders in the U.S. with a prevalence of 20%, resulting in a significant economic burden in direct and indirect costs. As these disorders affect millions of people worldwide, there is a surge in demand for effective therapeutic options, which is expected to drive market growth.

In addition, the development of biologic therapies has revolutionized the treatment landscape for gastrointestinal disorders, which further supports the market growth. Biologics, such as monoclonal antibodies and cytokine inhibitors, provide targeted interventions that modify the inflammatory processes associated with disorders such as Crohn's disease and ulcerative colitis. Furthermore, ongoing research and development activities in the field of gastrointestinal therapeutics contribute toward the market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available gastrointestinal therapeutics. For instance, Inspirna, Inc. is conducting a phase 1 study of RGX-202-01 (Ompenaclid) as combination therapy in 2nd Line RAS mutant advanced colorectal cancer. Thus, a rise in ongoing research and development activities in the field of gastrointestinal therapeutics is expected to drive the market growth.

The gastrointestinal therapeutics market is segmented into drug class, application, distribution channel, and region. By drug class, the market is segregated into biologics, proton pump inhibitors, aminosalicylates, antacids, laxatives, H2 antagonists, and others. By application, the market is classified into inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, and others. The inflammatory bowel disease segment is further categorized into Crohn’s disease and ulcerative colitis. The peptic ulcer disease segment further categorized into the gastric ulcer and duodenal ulcer. By distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Others). 

Major key players that operate in the gastrointestinal therapeutics market are AbbVie Inc., Pfizer Inc., AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Organon Group of Companies, Bausch Health Companies Inc., Cosmo Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Bristol-Myers Squibb Company. Key players have adopted product launch, product approval, and clinical trial as key developmental strategies to improve the product portfolio of the gastrointestinal therapeutics market.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastrointestinal therapeutics market analysis from 2022 to 2032 to identify the prevailing gastrointestinal therapeutics market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the gastrointestinal therapeutics market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global gastrointestinal therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Regulatory Guidelines

● Additional company profiles with specific to client's interest

● Additional country or region analysis- market size and forecast

● Expanded list for Company Profiles

● Historic market data

● Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

○ Bristol-Myers Squibb Compan

Scope of Gastrointestinal Therapeutics Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Moderate bargaining power of suppliers

3.3.2. Moderate threat of new entrants

3.3.3. Moderate threat of substitutes

3.3.4. Moderate intensity of rivalry

3.3.5. Moderate bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of gastrointestinal diseases

3.4.1.2. Rise in geriatric population

3.4.1.3. Rise in number of product launches

3.4.2. Restraints

3.4.2.1. Stringent government regulations toward approval of biosimilars

3.4.2.2. Patent expiry of drugs

3.4.3. Opportunities

3.4.3.1. Rise in R&D activities

3.4.3.2. Growth opportunities in emerging markets

4.1. Overview

4.1.1. Market size and forecast

4.2. Biologics

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Proton Pump Inhibitors

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Aminosalicylates

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Antacids

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

4.6. Laxatives

4.6.1. Key market trends, growth factors and opportunities

4.6.2. Market size and forecast, by region

4.6.3. Market share analysis by country

4.7. H2 Antagonists

4.7.1. Key market trends, growth factors and opportunities

4.7.2. Market size and forecast, by region

4.7.3. Market share analysis by country

4.8. Others

4.8.1. Key market trends, growth factors and opportunities

4.8.2. Market size and forecast, by region

4.8.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Inflammatory Bowel Disease

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.2.4. Inflammatory Bowel Disease Gastrointestinal Therapeutics Market by Type

5.3. Gastroesophageal Reflux Disease

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Peptic Ulcer Disease

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.4.4. Peptic Ulcer Disease Gastrointestinal Therapeutics Market by Type

5.5. Irritable Bowel Syndrome

5.5.1. Key market trends, growth factors and opportunities

5.5.2. Market size and forecast, by region

5.5.3. Market share analysis by country

5.6. Others

5.6.1. Key market trends, growth factors and opportunities

5.6.2. Market size and forecast, by region

5.6.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Drug Stores and Retail Pharmacies

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Online Providers

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by Drug Class

7.2.3. Market size and forecast, by Application

7.2.4. Market size and forecast, by Distribution Channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Market size and forecast, by Drug Class

7.2.5.1.2. Market size and forecast, by Application

7.2.5.1.3. Market size and forecast, by Distribution Channel

7.2.5.2. Canada

7.2.5.2.1. Market size and forecast, by Drug Class

7.2.5.2.2. Market size and forecast, by Application

7.2.5.2.3. Market size and forecast, by Distribution Channel

7.2.5.3. Mexico

7.2.5.3.1. Market size and forecast, by Drug Class

7.2.5.3.2. Market size and forecast, by Application

7.2.5.3.3. Market size and forecast, by Distribution Channel

7.3. Europe

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by Drug Class

7.3.3. Market size and forecast, by Application

7.3.4. Market size and forecast, by Distribution Channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Market size and forecast, by Drug Class

7.3.5.1.2. Market size and forecast, by Application

7.3.5.1.3. Market size and forecast, by Distribution Channel

7.3.5.2. France

7.3.5.2.1. Market size and forecast, by Drug Class

7.3.5.2.2. Market size and forecast, by Application

7.3.5.2.3. Market size and forecast, by Distribution Channel

7.3.5.3. UK

7.3.5.3.1. Market size and forecast, by Drug Class

7.3.5.3.2. Market size and forecast, by Application

7.3.5.3.3. Market size and forecast, by Distribution Channel

7.3.5.4. Italy

7.3.5.4.1. Market size and forecast, by Drug Class

7.3.5.4.2. Market size and forecast, by Application

7.3.5.4.3. Market size and forecast, by Distribution Channel

7.3.5.5. Spain

7.3.5.5.1. Market size and forecast, by Drug Class

7.3.5.5.2. Market size and forecast, by Application

7.3.5.5.3. Market size and forecast, by Distribution Channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Market size and forecast, by Drug Class

7.3.5.6.2. Market size and forecast, by Application

7.3.5.6.3. Market size and forecast, by Distribution Channel

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by Drug Class

7.4.3. Market size and forecast, by Application

7.4.4. Market size and forecast, by Distribution Channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Market size and forecast, by Drug Class

7.4.5.1.2. Market size and forecast, by Application

7.4.5.1.3. Market size and forecast, by Distribution Channel

7.4.5.2. China

7.4.5.2.1. Market size and forecast, by Drug Class

7.4.5.2.2. Market size and forecast, by Application

7.4.5.2.3. Market size and forecast, by Distribution Channel

7.4.5.3. India

7.4.5.3.1. Market size and forecast, by Drug Class

7.4.5.3.2. Market size and forecast, by Application

7.4.5.3.3. Market size and forecast, by Distribution Channel

7.4.5.4. Australia

7.4.5.4.1. Market size and forecast, by Drug Class

7.4.5.4.2. Market size and forecast, by Application

7.4.5.4.3. Market size and forecast, by Distribution Channel

7.4.5.5. South Korea

7.4.5.5.1. Market size and forecast, by Drug Class

7.4.5.5.2. Market size and forecast, by Application

7.4.5.5.3. Market size and forecast, by Distribution Channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Market size and forecast, by Drug Class

7.4.5.6.2. Market size and forecast, by Application

7.4.5.6.3. Market size and forecast, by Distribution Channel

7.5. LAMEA

7.5.1. Key market trends, growth factors and opportunities

7.5.2. Market size and forecast, by Drug Class

7.5.3. Market size and forecast, by Application

7.5.4. Market size and forecast, by Distribution Channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Market size and forecast, by Drug Class

7.5.5.1.2. Market size and forecast, by Application

7.5.5.1.3. Market size and forecast, by Distribution Channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Market size and forecast, by Drug Class

7.5.5.2.2. Market size and forecast, by Application

7.5.5.2.3. Market size and forecast, by Distribution Channel

7.5.5.3. South Africa

7.5.5.3.1. Market size and forecast, by Drug Class

7.5.5.3.2. Market size and forecast, by Application

7.5.5.3.3. Market size and forecast, by Distribution Channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Market size and forecast, by Drug Class

7.5.5.4.2. Market size and forecast, by Application

7.5.5.4.3. Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. AbbVie Inc.

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. AstraZeneca plc

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.2.7. Key strategic moves and developments

9.3. Pfizer Inc.

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.4. Bayer AG

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. Bausch Health Companies Inc.

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.6. Takeda Pharmaceutical Company Limited

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. Cosmo Pharmaceuticals

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Organon Group of Companies

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Bristol-Myers Squibb Company

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.9.7. Key strategic moves and developments

9.10. Teva Pharmaceutical Industries Limited

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performance

9.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 02. GASTROINTESTINAL THERAPEUTICS MARKET FOR BIOLOGICS, BY REGION, 2022-2032 ($MILLION)

TABLE 03. GASTROINTESTINAL THERAPEUTICS MARKET FOR PROTON PUMP INHIBITORS, BY REGION, 2022-2032 ($MILLION)

TABLE 04. GASTROINTESTINAL THERAPEUTICS MARKET FOR AMINOSALICYLATES, BY REGION, 2022-2032 ($MILLION)

TABLE 05. GASTROINTESTINAL THERAPEUTICS MARKET FOR ANTACIDS, BY REGION, 2022-2032 ($MILLION)

TABLE 06. GASTROINTESTINAL THERAPEUTICS MARKET FOR LAXATIVES, BY REGION, 2022-2032 ($MILLION)

TABLE 07. GASTROINTESTINAL THERAPEUTICS MARKET FOR H2 ANTAGONISTS, BY REGION, 2022-2032 ($MILLION)

TABLE 08. GASTROINTESTINAL THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 09. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 10. GASTROINTESTINAL THERAPEUTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2022-2032 ($MILLION)

TABLE 11. GLOBAL INFLAMMATORY BOWEL DISEASE GASTROINTESTINAL THERAPEUTICS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 12. GASTROINTESTINAL THERAPEUTICS MARKET FOR GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2022-2032 ($MILLION)

TABLE 13. GASTROINTESTINAL THERAPEUTICS MARKET FOR PEPTIC ULCER DISEASE, BY REGION, 2022-2032 ($MILLION)

TABLE 14. GLOBAL PEPTIC ULCER DISEASE GASTROINTESTINAL THERAPEUTICS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 15. GASTROINTESTINAL THERAPEUTICS MARKET FOR IRRITABLE BOWEL SYNDROME, BY REGION, 2022-2032 ($MILLION)

TABLE 16. GASTROINTESTINAL THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 17. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 18. GASTROINTESTINAL THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 19. GASTROINTESTINAL THERAPEUTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 20. GASTROINTESTINAL THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)

TABLE 21. GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 22. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 23. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 24. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 25. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 26. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 27. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 28. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 29. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 30. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 31. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 32. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 33. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 34. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 35. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 36. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 37. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 38. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 39. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 40. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 41. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 42. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 43. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 44. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 45. UK GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 46. UK GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 47. UK GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 48. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 49. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 50. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 51. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 52. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 53. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 54. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 55. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 56. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 57. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 58. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 59. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 60. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 61. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 62. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 63. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 64. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 65. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 66. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 67. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 68. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 69. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 70. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 71. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 72. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 73. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 74. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 75. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 76. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 77. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 78. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 79. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 80. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 81. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 82. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 83. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 84. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 85. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 86. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 87. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 88. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 89. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 90. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 91. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 92. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 93. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 94. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 95. ABBVIE INC.: KEY EXECUTIVES

TABLE 96. ABBVIE INC.: COMPANY SNAPSHOT

TABLE 97. ABBVIE INC.: PRODUCT SEGMENTS

TABLE 98. ABBVIE INC.: PRODUCT PORTFOLIO

TABLE 99. ABBVIE INC.: KEY STRATERGIES

TABLE 100. ASTRAZENECA PLC: KEY EXECUTIVES

TABLE 101. ASTRAZENECA PLC: COMPANY SNAPSHOT

TABLE 102. ASTRAZENECA PLC: PRODUCT SEGMENTS

TABLE 103. ASTRAZENECA PLC: PRODUCT PORTFOLIO

TABLE 104. ASTRAZENECA PLC: KEY STRATERGIES

TABLE 105. PFIZER INC.: KEY EXECUTIVES

TABLE 106. PFIZER INC.: COMPANY SNAPSHOT

TABLE 107. PFIZER INC.: PRODUCT SEGMENTS

TABLE 108. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 109. BAYER AG: KEY EXECUTIVES

TABLE 110. BAYER AG: COMPANY SNAPSHOT

TABLE 111. BAYER AG: PRODUCT SEGMENTS

TABLE 112. BAYER AG: PRODUCT PORTFOLIO

TABLE 113. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES

TABLE 114. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT

TABLE 115. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS

TABLE 116. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO

TABLE 117. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES

TABLE 118. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT

TABLE 119. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS

TABLE 120. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO

TABLE 121. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES

TABLE 122. COSMO PHARMACEUTICALS: KEY EXECUTIVES

TABLE 123. COSMO PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 124. COSMO PHARMACEUTICALS: PRODUCT SEGMENTS

TABLE 125. COSMO PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 126. ORGANON GROUP OF COMPANIES: KEY EXECUTIVES

TABLE 127. ORGANON GROUP OF COMPANIES: COMPANY SNAPSHOT

TABLE 128. ORGANON GROUP OF COMPANIES: PRODUCT SEGMENTS

TABLE 129. ORGANON GROUP OF COMPANIES: PRODUCT PORTFOLIO

TABLE 130. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES

TABLE 131. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT

TABLE 132. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS

TABLE 133. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

TABLE 134. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES

TABLE 135. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES

TABLE 136. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 137. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS

TABLE 138. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 139. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF GASTROINTESTINAL THERAPEUTICS MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN GASTROINTESTINAL THERAPEUTICS MARKET (2023-2032)

FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05. MODERATE THREAT OF NEW ENTRANTS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. MODERATE INTENSITY OF RIVALRY

FIGURE 08. MODERATE BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022 AND 2032(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR BIOLOGICS, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR PROTON PUMP INHIBITORS, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR AMINOSALICYLATES, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR ANTACIDS, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR LAXATIVES, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR H2 ANTAGONISTS, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR PEPTIC ULCER DISEASE, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR IRRITABLE BOWEL SYNDROME, BY COUNTRY 2022 AND 2032(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 24. GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)

FIGURE 25. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 27. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 28. GASTROINTESTINAL THERAPEUTICS MARKET BY REGION, 2022 AND 2032(%)

FIGURE 29. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 30. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 31. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 32. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 33. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 34. UK GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 35. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 36. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 37. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 38. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 39. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 40. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 41. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 42. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 43. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 44. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 45. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 46. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 47. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)

FIGURE 48. TOP WINNING STRATEGIES, BY YEAR (2021-2023)

FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)

FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)

FIGURE 51. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 52. COMPETITIVE DASHBOARD

FIGURE 53. COMPETITIVE HEATMAP: GASTROINTESTINAL THERAPEUTICS MARKET

FIGURE 54. TOP PLAYER POSITIONING, 2022

FIGURE 55. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 56. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 57. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 58. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)

FIGURE 59. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 60. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 61. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 62. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 63. BAYER AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 64. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 65. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 66. BAUSCH HEALTH COMPANIES INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 67. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 68. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 69. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2021-2023 ($MILLION)

FIGURE 70. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE BY REGION, 2023 (%)

FIGURE 71. COSMO PHARMACEUTICALS: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 72. ORGANON GROUP OF COMPANIES: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 73. ORGANON GROUP OF COMPANIES: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 74. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)

FIGURE 75. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 76. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 77. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%